Vacuum ultraviolet radiation and solid state physics semiannual status reports no. 1, 2, and 3, period ending 28 feb. 1963

Spectroscopic instruments for vacuum ultraviolet radiation stud

Vacuum ultraviolet radiation and solid state physics Semiannual status report no. 7, period ending 31 Aug. 1965

Vacuum ultraviolet radiation and solid state physics - optical constants for barium and silver surfaces and thin film

Development of a high-intensity, nanosecond, pulsed vacuum ultraviolet light source Final technical report, Oct. 1966 - Jan. 1968

High intensity, nanosecond, pulsed vacuum ultraviolet light sourc

Instrumentation problems in the vacuum ultraviolet below 1000 angstroms

Improved techniques for solving inherent instrumentation problems in vacuum ultraviolet below 1000 Angstrom

The measurement of optical constants in the vacuum UV region Final report, 1 Nov. 1961 - 30 Jun. 1969

Combination of ultrahigh vacuum monochromator with ultrahigh vacuum reflectometer for measuring optical constants of solid

Optical Constants of Silver and Barium in the Vacuum Ultraviolet Spectral Region

Optical constants of silver and barium in vacuum ultraviolet spectral regio

Far ultraviolet response of silicon P-N JUNCTION photodiodes

Silicon P-N junction photodiode resistivity in vacuum ultraviole

A note on maximal estimates for stochastic convolutions

In stochastic partial differential equations it is important to have pathwise regularity properties of stochastic convolutions. In this note we present a new sufficient condition for the pathwise continuity of stochastic convolutions in Banach spaces.Comment: Minor correction

Association of chronic obstructive pulmonary disease with morbidity and mortality in patients with peripheral artery disease: insights from the EUCLID trial

Background: Patients with chronic obstructive pulmonary disease (COPD) are at increased risk of developing lower extremity peripheral artery disease (PAD) and suffering PAD-related morbidity and mortality. However, the effect and burden of COPD on patients with PAD is less well defined. This post hoc analysis from EUCLID aimed to analyze the risk of major adverse cardiovascular events (MACE) and major adverse limb events (MALE) in patients with PAD and concomitant COPD compared with those without COPD, and to describe the adverse events specific to patients with COPD. Methods: EUCLID randomized 13,885 patients with symptomatic PAD to monotherapy with either ticagrelor or clopidogrel for the prevention of MACE. In this analysis, MACE, MALE, mortality, and adverse events were compared between groups with and without COPD using unadjusted and adjusted Cox proportional hazards model. Results: Of the 13,883 patients with COPD status available at baseline, 11% (n=1538) had COPD. Patients with COPD had a higher risk of MACE (6.02 vs 4.29 events/100 patient-years; p< 0.001) due to a significantly higher risk of myocardial infarction (MI) (3.55 vs 1.85 events/100 patient-years; p< 0.001) when compared with patients without COPD. These risks persisted after adjustment (MACE: adjusted hazard ratio (aHR) 1.30, 95% confidence interval [CI] 1.11– 1.52; p< 0.001; MI: aHR 1.45, 95% CI 1.18– 1.77; p< 0.001). However, patients with COPD did not have an increased risk of MALE or major bleeding. Patients with COPD were more frequently hospitalized for dyspnea and pneumonia (2.66 vs 0.9 events/100 patient-years; aHR 2.77, 95% CI 2.12– 3.63; p< 0.001) and more frequently discontinued study drug prematurely (19.36 vs 12.54 events/100 patient-years; p< 0.001; aHR 1.34, 95% CI 1.22– 1.47; p< 0.001). Conclusion: In patients with comorbid PAD and COPD, the risks of MACE, respiratory-related adverse events, and premature study drug discontinuation were higher when compared with patients without COPD. Registration: ClinicalTrials.gov: NCT01732822

Hospitalists in Teaching Hospitals: Opportunities but Not Without Danger

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/73210/1/j.1525-1497.2004.42002.x.pd